Gällande vårdprogram Hodgkins lymfom

Fastställt av Regionala cancercentrum i samverkan 2018-03-16.

22. Referenser

1. Nordcan hemsida, http:// NORDCAN.
2. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program. 2009:523-31.
3. Hjalgrim H, Seow A, Rostgaard K, Friborg J. Changing patterns of Hodgkin lymphoma incidence in Singapore. Int J Cancer. 2008;123(3):716-9.
4. Caporaso NE, Goldin LR, Anderson WF, Landgren O. Current insight on trends, causes, and mechanisms of Hodgkin's lymphoma. Cancer J. 2009;15(2):117-23.
5. Hjalgrim H, Askling J, Pukkala E, Hansen S, Munksgaard L, Frisch M. Incidence of Hodgkin's disease in Nordic countries. Lancet. 2001;358(9278):297-8.
6. Hjalgrim H. On the aetiology of Hodgkin lymphoma. Dan Med J. 2012;59(7):B4485.
7. Hjalgrim H, Askling J, Rostgaard K, Hamilton-Dutoit S, Frisch M, Zhang JS, et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med. 2003;349(14):1324-32.
8. Martis N, Mounier N. Hodgkin lymphoma in patients with HIV infection: a review. Curr Hematol Malig Rep. 2012;7(3):228-34.
9. Rios A. HIV-related hematological malignancies: a concise review. Clin Lymphoma Myeloma Leuk. 2014;14 Suppl:S96-103.
10. Mack TM, Cozen W, Shibata DK, Weiss LM, Nathwani BN, Hernandez AM, et al. Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. N Engl J Med. 1995;332(7):413-8.
11. Diepstra A, Niens M, Vellenga E, van Imhoff GW, Nolte IM, Schaapveld M, et al. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma. Lancet. 2005;365(9478):2216-24.
12. Kamper-Jorgensen M, Rostgaard K, Glaser SL, Zahm SH, Cozen W, Smedby KE, et al. Cigarette smoking and risk of Hodgkin lymphoma and its subtypes: a pooled analysis from the International Lymphoma Epidemiology Consortium (InterLymph). Ann Oncol. 2013;24(9):2245-55.
13. Fallah M, Liu X, Ji J, Forsti A, Sundquist K, Hemminki K. Hodgkin lymphoma after autoimmune diseases by age at diagnosis and histological subtype. Ann Oncol. 2014;25(7):1397-404.
14. Hollander P, Rostgaard K, Smedby KE, Chang ET, Amini RM, de Nully Brown P, et al. Autoimmune and Atopic Disorders and Risk of Classical Hodgkin Lymphoma. Am J Epidemiol. 2015;182(7):624-32.
15. Carbone A, Spina M, Gloghini A, Tirelli U. Classical Hodgkin's lymphoma arising in different host's conditions: pathobiology parameters, therapeutic options, and outcome. Am J Hematol. 2011;86(2):170-9.
16. Goldin LR, Bjorkholm M, Kristinsson SY, Turesson I, Landgren O. Highly increased familial risks for specific lymphoma subtypes. Br J Haematol. 2009;146(1):91-4.
17. Altieri A, Hemminki K. The familial risk of Hodgkin's lymphoma ranks among the highest in the Swedish Family-Cancer Database. Leukemia. 2006;20(11):2062-3.
18. Cerhan JR, Slager SL. Familial predisposition and genetic risk factors for lymphoma. Blood. 2015;126(20):2265-73.
19. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-68.
20. El-Galaly TC, d'Amore F, Mylam KJ, de Nully Brown P, Bogsted M, Bukh A, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol. 2012;30(36):4508-14.
21. World Health Organization WHO classification of tumours of haematopoietic and lymphoid tissues (4th ed.)International Agency for Research on Cancer, Lyon (2008). .
22. Hematopathology Elsevier Saunders 2011. Jaffe ES, Harris NL, Vardiman JW, Campo E, Arber DA.
23. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-90.
24. Kuppers R. New insights in the biology of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2012;2012:328-34.
25. Kuppers R, Engert A, Hansmann ML. Hodgkin lymphoma. J Clin Invest. 2012;122(10):3439-47.
26. Dunleavy K, Grant C, Eberle FC, Pittaluga S, Jaffe ES, Wilson WH. Gray zone lymphoma: better treated like hodgkin lymphoma or mediastinal large B-cell lymphoma? Curr Hematol Malig Rep. 2012;7(3):241-7.
27. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7(11):1630-6.
28. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339(21):1506-14.
29. Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol. 2005;23(30):7614-20.
30. Ferme C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007;357(19):1916-27.
31. Hoskin PJ, Diez P, Williams M, Lucraft H, Bayne M, Participants of the Lymphoma Radiotherapy G. Recommendations for the use of radiotherapy in nodal lymphoma. Clin Oncol (R Coll Radiol). 2013;25(1):49-58.
32. Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med. 2012;366(5):399-408.
33. Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363(7):640-52.
34. Boll B, Goergen H, Behringer K, Brockelmann PJ, Hitz F, Kerkhoff A, et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016;127(18):2189-92.
35. Stamatoullas A, Brice P, Bouabdallah R, Mareschal S, Camus V, Rahal I, et al. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol. 2015;170(2):179-84.
36. Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 2015;385(9976):1418-27.
37. Johnson P, Federico M, Kirkwood A, Fossa A, Berkahn L, Carella A, et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. N Engl J Med. 2016;374(25):2419-29.
38. Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F, et al. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. J Clin Oncol. 2016;34(11):1175-81.
39. Kedmi M, Apel A, Davidson T, Levi I, Dann EJ, Polliack A, et al. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan. Acta Haematol. 2016;135(3):156-61.
40. Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791-9.
41. Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol. 2013;161(1):76-86.
42. Enblad G, Glimelius B, Sundstrom C. Treatment outcome in Hodgkin's disease in patients above the age of 60: a population-based study. Ann Oncol. 1991;2(4):297-302.
43. Eichenauer DA, Fuchs M, Pluetschow A, Klimm B, Halbsguth T, Boll B, et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood. 2011;118(16):4363-5.
44. Advani RH, Horning SJ, Hoppe RT, Daadi S, Allen J, Natkunam Y, et al. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol. 2014;32(9):912-8.
45. Yildiz F, Zengin N, Engin H, Gullu I, Barista I, Caglar M, et al. Prospective study of combined modality treatment or radiotherapy alone in the management of early-stage adult Hodgkin's disease. Int J Radiat Oncol Biol Phys. 2004;60(3):839-46.
46. Solanki AA, LeMieux MH, Chiu BC, Mahmood U, Hasan Y, Koshy M. Long-term outcomes in patients with early stage nodular lymphocyte-predominant Hodgkin's lymphoma treated with radiotherapy. PLoS One. 2013;8(9):e75336.
47. Parikh RR, Grossbard ML, Harrison LB, Yahalom J. Early-stage nodular lymphocyte-predominant Hodgkin lymphoma: the impact of radiotherapy on overall survival. Leuk Lymphoma. 2015:1-8.
48. Canellos GP, Mauch P. What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin's lymphoma? J Clin Oncol. 2010;28(1):e8.
49. American Society of Hematology, Annual meeting 2011, abstract 2812.
50. Specht L, Yahalom J, Illidge T, Berthelsen AK, Constine LS, Eich HT, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89(4):854-62.
51. Petersen PM, Aznar MC, Berthelsen AK, Loft A, Schut DA, Maraldo M, et al. Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma: benefit of deep inspiration breath-hold. Acta Oncol. 2015;54(1):60-6.
52. Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048-58.
53. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25(24):3746-52.
54. Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica. 2006;91(4):475-81.
55. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107(1):52-9.
56. Kostakoglu L, Goldsmith SJ, Leonard JP, Christos P, Furman RR, Atasever T, et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer. 2006;107(11):2678-87.
57. Barrington SF, Kirkwood AA, Franceschetto A, Fulham MJ, Roberts TH, Almquist H, et al. PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood. 2016;127(12):1531-8.
58. Meignan M, Barrington S, Itti E, Gallamini A, Haioun C, Polliack A. Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012. Leuk Lymphoma. 2014;55(1):31-7.
59. Cheson BD. The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am. 2007;21(5):841-54.
60. Sieniawski M, Franklin J, Nogova L, Glossmann JP, Schober T, Nisters-Backes H, et al. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma. J Clin Oncol. 2007;25(15):2000-5.
61. Rancea M, Monsef I, von Tresckow B, Engert A, Skoetz N. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. Cochrane Database Syst Rev. 2013(6):CD009411.
62. Moskowitz AJ, Schoder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16(3):284-92.
63. Glimelius I, Diepstra A. Novel treatment concepts in Hodgkin lymphoma. J Intern Med. 2016.
64. Sasse S, Alram M, Muller H, Smardova L, Metzner B, Doehner H, et al. Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group. Leuk Lymphoma. 2016;57(5):1067-73.
65. Ansell SM. Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol. 2012;87(12):1096-103.
66. Glimelius I, Ekberg S, Jerkeman M, Chang ET, Bjorkholm M, Andersson TM, et al. Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009-trends in cure proportions by clinical characteristics. Am J Hematol. 2015;90(12):1128-34.
67. Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853-62.
68. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183-9.
69. Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010;85(5):320-4.
70. Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol. 2017;35(19):2125-32.
71. Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283-94.
72. Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, et al. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. J Clin Oncol. 2016.
73. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4):311-9.
74. Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017;130(2):221-8.
75. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27(4):605-11.
76. Fardet L, Lambotte O, Meynard JL, Kamouh W, Galicier L, Marzac C, et al. Reactive haemophagocytic syndrome in 58 HIV-1-infected patients: clinical features, underlying diseases and prognosis. AIDS. 2010;24(9):1299-306.
77. Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500-10.
78. Behringer K, Mueller H, Goergen H, Thielen I, Eibl AD, Stumpf V, et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol. 2013;31(2):231-9.
79. Mahajan N. Fertility preservation in female cancer patients: An overview. J Hum Reprod Sci. 2015;8(1):3-13.
80. Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HA, Jr., Peccatori FA, et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med. 2016;14:1.
81. Eichenauer DA, Engert A, Andre M, Federico M, Illidge T, Hutchings M, et al. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii70-5.
82. Agarwal A, Ranganathan P, Kattal N, Pasqualotto F, Hallak J, Khayal S, et al. Fertility after cancer: a prospective review of assisted reproductive outcome with banked semen specimens. Fertil Steril. 2004;81(2):342-8.
83. Vermaete N, Wolter P, Verhoef G, Gosselink R. Physical activity, physical fitness and the effect of exercise training interventions in lymphoma patients: a systematic review. Ann Hematol. 2013;92(8):1007-21.
84. Baudino B, D'Agata F, Caroppo P, Castellano G, Cauda S, Manfredi M, et al. The chemotherapy long-term effect on cognitive functions and brain metabolism in lymphoma patients. Q J Nucl Med Mol Imaging. 2012;56(6):559-68.
85. Sjövall K. Patienters perspektiv och upplevelser av cancersjukdom och cancervård. In: Thomé B. HM, editor. Perspektiv på onkologisk vård. Lund: Studentlitteratur; 2011. p. 131-48.
86. Banakh I, Lam A, Tiruvoipati R, Carney I, Botha J. Imatinib for bleomycin induced pulmonary toxicity: a case report and evidence-base review. Clin Case Rep. 2016;4(5):486-90.
87. Carnevale-Schianca F, Gallo S, Rota-Scalabrini D, Sangiolo D, Fizzotti M, Caravelli D, et al. Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin's lymphoma: hope for severe chemotherapy-induced toxicity? J Clin Oncol. 2011;29(24):e691-3.
88. Yri OE, Torfoss D, Hungnes O, Tierens A, Waalen K, Nordoy T, et al. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood. 2011;118(26):6769-71.
89. Wells M, Macmillan M, Raab G, MacBride S, Bell N, MacKinnon K, et al. Does aqueous or sucralfate cream affect the severity of erythematous radiation skin reactions? A randomised controlled trial. Radiother Oncol. 2004;73(2):153-62.
90. Iwakawa M, Noda S, Yamada S, Yamamoto N, Miyazawa Y, Yamazaki H, et al. Analysis of non-genetic risk factors for adverse skin reactions to radiotherapy among 284 breast cancer patients. Breast Cancer. 2006;13(3):300-7.
91. Sharp L, Johansson H, Hatschek T, Bergenmar M. Smoking as an independent risk factor for severe skin reactions due to adjuvant radiotherapy for breast cancer. Breast. 2013;22(5):634-8.
92. Prochazka M, Granath F, Ekbom A, Shields PG, Hall P. Lung cancer risks in women with previous breast cancer. Eur J Cancer. 2002;38(11):1520-5.
93. Jagsi R, Griffith KA, Koelling T, Roberts R, Pierce LJ. Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer. 2007;109(4):650-7.
94. Kaufman EL, Jacobson JS, Hershman DL, Desai M, Neugut AI. Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol. 2008;26(3):392-8.
95. Macdonald G, Kondor N, Yousefi V, Green A, Wong F, Aquino-Parsons C. Reduction of carboxyhaemoglobin levels in the venous blood of cigarette smokers following the administration of carbogen. Radiother Oncol. 2004;73(3):367-71.
96. Peterson C. Naturläkemedel - egenvård på egen risk! Fara för okända biverkningar och interaktioner med "vanliga" läkemedel. . Läkartidningen. 2005:102.
97. Malekzadeh F, et al. Naturläkemedel och hormonpreparat - potentiell risk för bröstcancerpatienter 2005:102.
98. Bradley KA, Rubinsky AD, Sun H, Bryson CL, Bishop MJ, Blough DK, et al. Alcohol screening and risk of postoperative complications in male VA patients undergoing major non-cardiac surgery. J Gen Intern Med. 2011;26(2):162-9.
99. Nath B, Li Y, Carroll JE, Szabo G, Tseng JF, Shah SA. Alcohol exposure as a risk factor for adverse outcomes in elective surgery. J Gastrointest Surg. 2010;14(11):1732-41.
100. Tonnesen H, Nielsen PR, Lauritzen JB, Moller AM. Smoking and alcohol intervention before surgery: evidence for best practice. Br J Anaesth. 2009;102(3):297-306.
101. Gustavsson A, Eskilsson J, Landberg T, Svahn-Tapper G, White T, Wollmer P, et al. Late cardiac effects after mantle radiotherapy in patients with Hodgkin's disease. Ann Oncol. 1990;1(5):355-63.
102. van Nimwegen FA, Schaapveld M, Janus CP, Krol AD, Petersen EJ, Raemaekers JM, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175(6):1007-17.
103. Ng AK. Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematol. 2011;154(1):23-31.
104. Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290(21):2831-7.
105. Galper SL, Yu JB, Mauch PM, Strasser JF, Silver B, Lacasce A, et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood. 2011;117(2):412-8.
106. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol. 1993;11(7):1208-15.
107. Myrehaug S, Pintilie M, Tsang R, Mackenzie R, Crump M, Chen Z, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma. 2008;49(8):1486-93.
108. Andersson A, Naslund U, Tavelin B, Enblad G, Gustavsson A, Malmer B. Long-term risk of cardiovascular disease in Hodgkin lymphoma survivors--retrospective cohort analyses and a concept for prospective intervention. Int J Cancer. 2009;124(8):1914-7.
109. Sieswerda E, Postma A, van Dalen EC, van der Pal HJ, Tissing WJ, Rammeloo LA, et al. The Dutch Childhood Oncology Group guideline for follow-up of asymptomatic cardiac dysfunction in childhood cancer survivors. Ann Oncol. 2012;23(8):2191-8.
110. Thompson CA, Mauck K, Havyer R, Bhagra A, Kalsi H, Hayes SN. Care of the adult Hodgkin lymphoma survivor. Am J Med. 2011;124(12):1106-12.
111. Abrahamsen AF, Loge JH, Hannisdal E, Nome O, Lund MB, Holte H, et al. Late medical sequelae after therapy for supradiaphragmatic Hodgkin's disease. Acta Oncol. 1999;38(4):511-5.
112. Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst. 1993;85(1):25-31.
113. Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol. 2002;20(16):3484-94.
114. Horwich A, Swerdlow AJ. Second primary breast cancer after Hodgkin's disease. Br J Cancer. 2004;90(2):294-8.
115. Hodgson DC, Gilbert ES, Dores GM, Schonfeld SJ, Lynch CF, Storm H, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol. 2007;25(12):1489-97.
116. Lord SJ, Lei W, Craft P, Cawson JN, Morris I, Walleser S, et al. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer. 2007;43(13):1905-17.
117. van Hulst RA, Rietbroek RC, Gaastra MT, Schlosser NJ. To dive or not to dive with bleomycin: a practical algorithm. Aviat Space Environ Med. 2011;82(8):814-8.
118. Swerdlow AJ, Cooke R, Bates A, Cunningham D, Falk SJ, Gilson D, et al. Risk of premature menopause after treatment for Hodgkin's lymphoma. J Natl Cancer Inst. 2014;106(9).
119. Weibull CE, Eloranta S, Smedby KE, Bjorkholm M, Kristinsson SY, Johansson AL, et al. Pregnancy and the Risk of Relapse in Patients Diagnosed With Hodgkin Lymphoma. J Clin Oncol. 2016;34(4):337-44.
120. Stensheim H, Klungsoyr K, Skjaerven R, Grotmol T, Fossa SD. Birth outcomes among offspring of adult cancer survivors: a population-based study. Int J Cancer. 2013;133(11):2696-705.
121. Delforoush M, Berglund M, Edqvist PH, Sundstrom C, Gullbo J, Enblad G. Expression of possible targets for new proteasome inhibitors in diffuse large B-cell lymphoma. Eur J Haematol. 2017;98(1):52-6.
122. Molin D, Linderoth J, Wahlin BE. Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: an analysis of the Swedish Lymphoma Registry. Br J Haematol. 2017;177(3):449-56.